GLP‑1 receptor agonist therapy and 2‑year structural outcomes after arthroscopic rotator cuff repair in type 2 diabetes
Mao Yi Yang, Li Wei Hung · 2026
Read GLP‑1 receptor agonist therapy and 2‑year structural outcomes after arthroscopic rotator cuff repair in type 2 diabetes by Mao Yi Yang, Li Wei Hung (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13474731.txt.
Description
Yang and Hung used the TriNetX medical records network, spanning over 170 healthcare organizations, to ask whether GLP-1 diabetes drugs taken before shoulder surgery compromise tendon healing after rotator cuff repair. Their 2026 study matched 957 diabetic patients who had started a GLP-1 drug within six months before repair against 957 on other diabetes therapy, balancing age, weight, and blood sugar.
Two years out, the feared harm did not appear. Revision surgery occurred in 1.0% of GLP-1 users and 1.1% of comparators, a risk ratio of 0.91 with a confidence interval comfortably crossing no-effect, and retear-proxy events ran 7.3% versus 8.6% in GLP-1 users' favor. Survival curves showed no significant separation on either endpoint. The authors call the drugs structurally safe around this surgery on current evidence, pending imaging-confirmed prospective studies.
Catalog record
| CREATOR | Mao Yi Yang, Li Wei Hung |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 31 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |